TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19209082

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 27
Study: 17597461

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg single dose as adjunct to quinine)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Quinine treatment alone
Number of subjects: 21
Study: 15234038

Group type: EXPERIMENTAL
Intervention: I‐125
Number of subjects: 148

Group type: COMPARATOR
Intervention: Pd‐103
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: R300
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Number of perirectal seeds ≤2.0 mm from rectal wall
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Number of perirectal seeds 2‐4 mm from rectal wall
Number of subjects: 148
Study: 11435528

Group type: EXPERIMENTAL
Intervention: Ca-HMB (3 g/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9736848

Group type: EXPERIMENTAL
Intervention: Clinical information plus information about barriers to behavioral change (study group)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Clinical information only (control group)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both study and control groups (combined)
Number of subjects: 13
Study: 7914306

Group type: EXPERIMENTAL
Intervention: PRP-T vaccine (Hib conjugate vaccine) given by separate injection according to an accelerated 2, 3, and 4 month schedule without a booster dose in the second year of life.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis of PRP-T vaccine.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRP-T vaccine (Hib conjugate vaccine) with follow-up until November 1, 1993.
Number of subjects: 0
Study: 3056331

Group type: EXPERIMENTAL
Intervention: Thymopentin (TP‐5) 50 mg subcutaneously two hours preoperatively
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Thymopentin (TP‐5) 50 mg subcutaneously two hours preoperatively and 48 hours postoperatively
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30723168

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) for 30 min/session for 10 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no EMS)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) and Control group
Number of subjects: 33
Study: 27306255

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (100 μg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous morphine (5 ± 2 mg for 24 hours at 2 mL/h)
Number of subjects: 50
Study: 25255724

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) - intravenous infusion of 5000 IU/kg before anesthesia and at the start of surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological saline (Control group)
Number of subjects: 40
Study: 23545598

Group type: EXPERIMENTAL
Intervention: MA-I (intensive computer)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: EX-I (aerobic)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: MA-I/EX-I, MA-I/EX-C, MA-C/EX-I, MA-C/EX-C (all groups)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Physical plus mental activity (combined intervention)
Number of subjects: 126
Study: 22117989

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg orally three times daily) plus fenofibrate (200 mg orally once daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Metformin (500 mg orally three times daily) plus placebo
Number of subjects: 87
Study: 20183462

Group type: EXPERIMENTAL
Intervention: Herbal treatment for acute hepatitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16606971

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m2) administered on days 1, 4, 8, and 11 of a 3-week cycle
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 51
Study: 15764103

Group type: EXPERIMENTAL
Intervention: Peer-led classroom curriculum intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Peer-led intervention for regular riders
Number of subjects: 27
Study: 11316640

Group type: EXPERIMENTAL
Intervention: Salmeterol 42 microg twice daily
Number of subjects: 405

Group type: COMPARATOR
Intervention: Ipratropium bromide 36 microg four times daily
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 9137327

Group type: EXPERIMENTAL
Intervention: Raynaud phenomenon (RP) diagnosis confirmed by clinical examination and nailfold capillary microscopy.
Number of subjects: 2626

Group type: EXPERIMENTAL
Intervention: Age and occupation-related factors.
Number of subjects: 2626

Group type: EXPERIMENTAL
Intervention: Smoking status among men.
Number of subjects: 2626
Study: 8148464

Group type: EXPERIMENTAL
Intervention: Clinical therapeutic strategies aimed at inhibiting selected pathways
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental studies focusing on the activities of single cytokines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More precise delineation of the roles of each mechanism contributing to pathogenesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development of additional approaches to prevention and treatment
Number of subjects: 0
Study: 3555597

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream applied nightly after 5% 5-fluorouracil (5-FU) cream applied twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control cream applied nightly after 5% 5-fluorouracil (5-FU) cream applied twice daily
Number of subjects: 19
Study: 29458906

Group type: EXPERIMENTAL
Intervention: PEAK Plasma Blade
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 40
Study: 26917566

Group type: EXPERIMENTAL
Intervention: Poor collateral status (hypoperfusion intensity ratio ≤0.4)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Good collateral status (hypoperfusion intensity ratio >0.4)
Number of subjects: 141
Study: 25664215

Group type: EXPERIMENTAL
Intervention: Milnacipran (100-200 mg/d, dosed twice a day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 22376088

Group type: COMPARATOR
Intervention: Passive insulation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Forced-air skin surface warming for 10 min
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Forced-air skin surface warming for 20 min
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Forced-air skin surface warming for 30 min
Number of subjects: 200
Study: 20473258

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 0
Study: 19127785

Group type: EXPERIMENTAL
Intervention: Nicotine polyestex gum
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 16111420

Group type: EXPERIMENTAL
Intervention: Partial cochlear implant insertion (8 electrodes)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Full cochlear implant insertion
Number of subjects: 25
Study: 12051106

Group type: EXPERIMENTAL
Intervention: Synthesized pheromone, topically applied
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 10424386

Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin composite (compomer)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Resin composite
Number of subjects: 50
Study: 8685642

Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg b.i.d. per os)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Itraconazole (100 mg b.i.d. per os)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 123

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 123
Study: 2408250

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors
Number of subjects: 2000

Group type: COMPARATOR
Intervention: ISDN and Hydralazine
Number of subjects: 2000
Study: 379955

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Emetine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of metronidazole and emetine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgical management (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medical treatment (including antiamoebic drugs)
Number of subjects: 60
Study: 31240743

Group type: EXPERIMENTAL
Intervention: Transcrestal sinus floor elevation (tSFE)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lateral sinus floor elevation (lSFE)
Number of subjects: 54
Study: 27548998

Group type: EXPERIMENTAL
Intervention: Fractional carbon dioxide laser combined with betamethasone and salicylic acid solution
Number of subjects: 2

Group type: COMPARATOR
Intervention: Betamethasone and salicylic acid solution
Number of subjects: 2
Study: 27626365

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy with hormones
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Control group (other treatments)
Number of subjects: 1643
Study: 25383998

Group type: EXPERIMENTAL
Intervention: DVD version of La CLAve psychoeducational program
Number of subjects: 218

Group type: COMPARATOR
Intervention: Psychoeducational program of similar length regarding caregiving (control group)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: DVD presentation administered by a community mental health educator
Number of subjects: 218
Study: 22813209

Group type: EXPERIMENTAL
Intervention: SYSTANE UD eye drops (preservative-free hydroxypropyl Guar) applied 5 times per day for 3 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: VISINE INTENSIV 1% EDO eye drops (preservative-free Tamarindus indica seed polysaccharide) applied 5 times per day for 3 months
Number of subjects: 28
Study: 20367987

Group type: EXPERIMENTAL
Intervention: Hemocoagulase Agkistrodon (2 U)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Hemocoagulase Atrox (control)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 432
Study: 17825417

Group type: EXPERIMENTAL
Intervention: 1-site phacotrabeculectomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2-site phacotrabeculectomy
Number of subjects: 90
Study: 16255877

Group type: EXPERIMENTAL
Intervention: anti-CD(4), CD(8) monoclonal antibodies combined with cyclosporine A
Number of subjects: 41

Group type: COMPARATOR
Intervention: anti-lymphocyte globulin and cyclosporine A
Number of subjects: 41
Study: 12434939

Group type: EXPERIMENTAL
Intervention: Barrier-specific telephone counseling (BSTC)
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Continuing medical education (CME)
Number of subjects: 1601
Study: 10354213

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (12 mmol L‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Euglycaemia (4 mmol L‐1)
Number of subjects: 12
Study: 7867053

Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish (VCHX)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish with fluoride (VCHXF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine-fluoride gel (GCHXF)
Number of subjects: 60
Study: 1552582

Group type: EXPERIMENTAL
Intervention: Low dose warfarin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intermittent pneumatic leg compression
Number of subjects: 100
Study: 3888766

Group type: EXPERIMENTAL
Intervention: Intramuscular ceruletide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fatty meal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Routine cholecystokinetic stimulation
Number of subjects: 100
Study: 30830545

Group type: EXPERIMENTAL
Intervention: Pie-cut pattern (PCP) fragmentation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Three-plane chop (TPC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No lens fragmentation (NLF)
Number of subjects: 100
Study: 29048247

Group type: EXPERIMENTAL
Intervention: Lustful intentions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Romantic intentions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intentions to not love or not lust
Number of subjects: 22
Study: 26409030

Group type: EXPERIMENTAL
Intervention: 0.2 mg sublingual buprenorphine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25347723

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review
Number of subjects: 209

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 209
Study: 24013610

Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21182555

Group type: EXPERIMENTAL
Intervention: Peer education intervention (PEI)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 690
Study: 19342470

Group type: EXPERIMENTAL
Intervention: Enhanced Coping Skills Training (CST) including sessions promoting physical activity, relaxation, cognitive restructuring, communication skills, and problem solving.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standardized Medical Care (SMC) including COPD education and symptom monitoring.
Number of subjects: 600
Study: 17917503

Group type: EXPERIMENTAL
Intervention: Darusentan (300 mg)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 15370723

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 11264560

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam and Fentanyl
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 9685512

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 38
Study: 8750995

Group type: EXPERIMENTAL
Intervention: Scleral buckling (group A)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Encircling elements (group B)
Number of subjects: 19
Study: 1789394

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (low dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7056273

Group type: EXPERIMENTAL
Intervention: Tolmesoxide (300‐900mg daily)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tolmesoxide taken with food
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tolmesoxide taken fasting
Number of subjects: 6
Study: 31652193

Group type: EXPERIMENTAL
Intervention: New suture method
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional suture method
Number of subjects: 80
Study: 31170967

Group type: EXPERIMENTAL
Intervention: School-based exercise intervention consisting of 3-min sessions of high intensity interval training combined with music, implemented two times a week at school during study periods.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 27764682

Group type: EXPERIMENTAL
Intervention: Milk containing 2.5ppm fluoride daily (T1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Milk containing 5.0ppm fluoride daily (T3)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Milk containing 2.5ppm fluoride every other day (T2)
Number of subjects: 5

Group type: COMPARATOR
Intervention: No treatment (T5)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Milk containing 5.0ppm fluoride every other day (T4)
Number of subjects: 5
Study: 25613235

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Number of subjects: 14
Study: 23690568

Group type: EXPERIMENTAL
Intervention: Bilingual vocabulary intervention
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: English-only vocabulary intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Mathematics intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 202
Study: 22531514

Group type: EXPERIMENTAL
Intervention: Conformal radiation and temozolamide
Number of subjects: 46
Study: 20180429

Group type: EXPERIMENTAL
Intervention: Shenfu Qiangjing Decoction (SQD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin C tablets plus intramuscular chymotrypsin (Control)
Number of subjects: 60
Study: 17587789

Group type: EXPERIMENTAL
Intervention: Lifestyle plus exercise intervention (LIFE+EX)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 44
Study: 15072861

Group type: EXPERIMENTAL
Intervention: 12‐week physical activity and diet intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 92
Study: 11471263

Group type: EXPERIMENTAL
Intervention: Tympanic thermometry
Number of subjects: 378

Group type: COMPARATOR
Intervention: Rectal thermometry
Number of subjects: 378
Study: 9495616

Group type: EXPERIMENTAL
Intervention: Brushing teeth after 48 hours of no cleaning
Number of subjects: 10

Group type: COMPARATOR
Intervention: No brushing teeth after 48 hours of no cleaning
Number of subjects: 10
Study: 8054332

Group type: EXPERIMENTAL
Intervention: Nutrition education course consisting of a video and booklet with motivational material
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group received a video and booklet with no motivational or simplified materials
Number of subjects: 264

Group type: COMPARATOR
Intervention: Baseline group received no tuition and represented a control of publicly available information
Number of subjects: 264
Study: 1659497

Group type: EXPERIMENTAL
Intervention: Kang Er Xin-I (KEX-I) for two weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Coenzyme Q10 (control)
Number of subjects: 26
Study: 6118964

Group type: EXPERIMENTAL
Intervention: Prazosin 0.5 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salbutamol 1 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30246888

Group type: EXPERIMENTAL
Intervention: 3D printed heart model workshop
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 20
Study: 27825975

Group type: EXPERIMENTAL
Intervention: Office insertion of Reveal LINQ ICM
Number of subjects: 521

Group type: COMPARATOR
Intervention: Hospital insertion of Reveal LINQ ICM
Number of subjects: 521
Study: 25773268

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 21162

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 21162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21162
Study: 24107738

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg, increased to 50 mg if needed after 4 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 21429079

Group type: EXPERIMENTAL
Intervention: Ice packs on the perineum
Number of subjects: 114

Group type: COMPARATOR
Intervention: Water packs at set temperature (placebo)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 114
Study: 18710427

Group type: EXPERIMENTAL
Intervention: peginterferon α-2a (40KD) plus ribavirin for 16 or 24 weeks
Number of subjects: 885

Group type: COMPARATOR
Intervention: Steatosis
Number of subjects: 885
Study: 17722868

Group type: EXPERIMENTAL
Intervention: Olyset nets
Number of subjects: 3

Group type: COMPARATOR
Intervention: Untreated nets
Number of subjects: 3

Group type: COMPARATOR
Intervention: No nets (control)
Number of subjects: 3
Study: 15103544

Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin beta (NeoRecormon) to maintain target Hb levels of 13‐15 g/dl
Number of subjects: 160

Group type: COMPARATOR
Intervention: Current practice (no epoetin therapy until Hb levels decline below 10.5 g/dl)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin beta (NeoRecormon)
Number of subjects: 160
Study: 11328423

Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clomiphene citrate, 50 mg/day, orally
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 42
Study: 9485848

Group type: EXPERIMENTAL
Intervention: Nursing care
Number of subjects: 0
Study: 7992099

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside and IFN-alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homoharringtonine followed by IFN-alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon-alpha post-transplant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 0
Study: 2463564

Group type: EXPERIMENTAL
Intervention: DDDMR (double chamber rate responsive cardiac pacemaker)
Number of subjects: 7

Group type: COMPARATOR
Intervention: VVIMR (single chamber rate responsive cardiac pacemaker)
Number of subjects: 7
Study: 29429908

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) with clobazam
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) without clobazam
Number of subjects: 108

Group type: COMPARATOR
Intervention: Clobazam alone
Number of subjects: 108
Study: 28295915

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study: 25300315

Group type: EXPERIMENTAL
Intervention: 4-layer compression bandaging + larvae
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4-layer compression bandaging
Number of subjects: 40
Study: 23052417

Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12